NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Andexanet alfa for reversing anticoagulation

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Company	<u>General</u>
Portola Pharmaceuticals (andexanet)	Allied Health Professionals Federation
alfa)	All Wales Therapeutics and Toxicology
Dationt/commonweal	Centre
Patient/carer groups	Board of Community Health Councils in
Black Health AgencyCirculation Foundation	Wales
M !! O !! (D!!!	British National Formulary Care Quality Commission
0 0 4 1 10 5 10	Care Quality Commission Department of Health, Social Services
	Department of Health, Social Services and Public Sefety for Northern Iroland
Specialised Healthcare AllianceThrombosis UK	and Public Safety for Northern IrelandHealthcare Improvement Scotland
THIOTIDOSIS OR	Hospital Information Services -
Professional groups	Jehovah's Witnesses
Association of Anaesthetists	Medicines and Healthcare products
Association of Surgeons of Great	Regulatory Agency
Britain and Ireland	National Association of Primary Care
British Association for Accident and	National Pharmacy Association
Emergency Medicine	NHS Alliance
British Association for Immediate Care	NHS Commercial Medicines Unit
British Cardiovascular Society	NHS Confederation
British Geriatrics Society	Scottish Medicines Consortium
British Trauma Society	
British Neuroscience Association	Possible comparator companies
British Orthopaedic Association	AAH Pharmaceuticals (tranexamic
British Society of Gastroenterology	acid)
British Society of Interventional	Accord Healthcare (tranexamic acid)
Radiology	AMCo (tranexamic acid)
British Society of Neuroradiologists	Bowmed Ibisqus (tranexamic acid)
British Society for Haematology	CSL Behring
British Society for Haemostasis and	Focus Pharmaceuticals (tranexamic
Thrombosis	acid)
British Institute of Radiology Dritish There is Consistent	Octapharma (prothrombin complex
British Thoracic Society Dritish Waits Institute	concerntrate)
British Vein Institute Clinical Landon of Thrombosis	Pfizer (tranexamic acid) Takeda
Clinical Leaders of Thrombosis Callaga of Baraga disa	Takeda
College of Paramedics	

Consultees	Commentators (no right to submit or appeal)
 Royal College of Anaesthetists Royal College of Emergency Medicine Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal Pharmaceutical Society Royal College of Physicians Royal College of Surgeons Royal Society of Medicine Society of British Neurological Surgeons Society of Cardiothoracic Surgeons Society of Vascular Technology Society of Vascular Nurses St Johns Ambulance The Intensive Care Society UK Clinical Pharmacy Association Vascular Anaesthesia Society of Great Britain and Ireland Vascular Society of Great Britain and Ireland Others Department of Health NHS England NHS Hounslow CCG NHS Sutton CCG Welsh Government 	 Other relevant companies Bayer (rivaroxaban) Bristol-Myers Squibb (apixaban) Pfizer (apixaban) Relevant research groups MRC Clinical Trials Unit National Centre for Cardiovascular Preventions and Outcomes National Institute for Health Research Thrombosis Research Institute Trauma Audit Research Network Wellcome Trust Associated Public Health Groups Public Health England Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

-

¹ Non company consultees are invited to submit statements relevant to the group they are representing.